Anti-Aging Peptide Stack: BPC-157, TB-500, Ipamorelin, and NAD+ in Research

Research Disclaimer: All compounds referenced are sold exclusively for in-vitro and laboratory research use. Not approved for human therapeutic use. This content does not constitute medical advice.

No single compound addresses the full complexity of biological aging. The most mechanistically thorough anti-aging research protocols combine compounds that act on distinct, non-overlapping aging hallmarks: cellular senescence, mitochondrial dysfunction, epigenetic changes, stem cell exhaustion, and impaired tissue homeostasis.

This article designs a research stack covering the four most researched pharmacological targets in anti-aging peptide research — tissue repair (BPC-157/TB-500), GH axis restoration (Ipamorelin + CJC-1295), and cellular energy/longevity pathways (NAD+/NMN) — and explains the mechanistic rationale for combining them.

Table of Contents#

1. The Hallmarks of Aging: What We're Targeting
2. Compound 1–2: BPC-157 + TB-500 (Tissue Repair)
3. Compound 3–4: Ipamorelin + CJC-1295 (GH Axis)
4. Compound 5: NAD+/NMN (Cellular Longevity)
5. Mechanism Map: Non-Overlapping Pathways
6. Full Anti-Aging Stack Protocol
7. Endpoint Selection for Anti-Aging Research
8. Considerations and Caveats
9. Key References

The Hallmarks of Aging: What We're Targeting#

López-Otín et al. (2013, updated 2023) identified 12 hallmarks of aging:

1. Genomic instability
2. Telomere attrition
3. Epigenetic alterations
4. Loss of proteostasis
5. Disabled macroautophagy
6. Deregulated nutrient sensing
7. Mitochondrial dysfunction
8. Cellular senescence
9. Stem cell exhaustion
10. Altered intercellular communication
11. Chronic inflammation
12. Dysbiosis

Our stack primarily targets:

• Stem cell exhaustion (BPC-157, TB-500, MGF): tissue repair and regeneration
• Mitochondrial dysfunction and deregulated nutrient sensing (NAD+/NMN → SIRT3, SIRT1): mitochondrial quality and biogenesis
• Altered intercellular communication and chronic inflammation (BPC-157: NO/anti-inflammatory; TB-500: IL-10; NAD+: NF-κB suppression via SIRT1)
• Loss of proteostasis (GH/IGF-1 via Ipamorelin + CJC-1295: mTOR-mediated protein quality control; NAD+/SIRT1: autophagy)

Compound 1–2: BPC-157 + TB-500 (Tissue Repair)#

BPC-157: FAK-paxillin and GI/Connective Tissue#

BPC-157 (Body Protection Compound 157) is a 15-amino-acid pentadecapeptide from gastric juice:

• Primary mechanism: FAK-paxillin pathway activation → cell migration, tendon-to-bone attachment, growth factor receptor upregulation
• Nitric oxide system: activates eNOS → vasodilation, angiogenesis
• GI tract: cytoprotective — protects against NSAID-induced and stress-induced ulcers; regenerates GI mucosa
• CNS: anti-depressant-like, neuroprotective (glutamate antagonism, dopamine modulation)

Aging relevance:

• Connective tissue repair capacity declines with age (reduced fibroblast activity, tendon matrix quality)
• GI permeability increases with age ("leaky gut") → systemic inflammation; BPC-157 repairs GI barrier
• Vascular function declines with age; BPC-157's NO/angiogenesis effects maintain vascular function

TB-500 (Thymosin β4 N-terminal fragment)#

TB-500 is the LKKTETQ fragment (4–14) of thymosin β4:

• Primary mechanism: G-actin sequestration → promotes free actin polymerization → cell migration, wound closure
• Anti-inflammatory: induces IL-10 (anti-inflammatory cytokine)
• ILK-Akt pathway: promotes cell survival and tissue remodeling
• VEGF: angiogenesis support
• Cardiac: reduces scar formation after myocardial injury

Aging relevance:

• Wound healing capacity declines with age (reduced actin dynamics, less fibroblast migration)
• Age-related decline in circulating thymosin β4 levels documented
• Anti-inflammatory IL-10 elevation counteracts age-related low-grade inflammation

Why combine BPC-157 and TB-500?#

They act through distinct, non-overlapping mechanisms:

• BPC-157: FAK-paxillin (attachment/tendon)
• TB-500: G-actin/LKKTETQ (migration/wound healing)

Combined, they cover the two primary tissue repair mechanisms. The Novinscak 2008 data (combined vs. monotherapy in muscle laceration model) showed greater repair with the combination.

Compound 3–4: Ipamorelin + CJC-1295 (GH Axis)#

Why the GH axis declines with aging#

Somatopause (age-related GH decline) produces:

• Decreased GH pulse amplitude (~14%/decade from age 30)
• Reduced IGF-1 → impaired muscle protein synthesis, reduced satellite cell activation, bone loss
• Increased visceral fat (GH's direct lipolytic effect is lost)
• Reduced bone density

Ipamorelin + CJC-1295 rationale#

• Ipamorelin (GHS-R1a agonist): stimulates pituitary GH release, suppresses somatostatin, selective (no cortisol/ACTH elevation)
• CJC-1295 without DAC (GHRH-R agonist): stimulates GHRH receptor → synergistic with Ipamorelin → 3–10× more GH than either alone

Together: restore pulsatile GH secretion toward younger-adult levels, within the natural feedback regulatory system (pituitary is still under hypothalamic control).

Aging relevance: directly addresses somatopause. Restores the GH/IGF-1 axis — driving muscle protein synthesis, satellite cell activation, bone density maintenance, and visceral fat reduction in aged animals.

Why use secretagogues rather than rhGH for anti-aging research?#

For aging research, secretagogues preserve:

• GH pulsatility: more physiological, less receptor downregulation
• Feedback regulation: natural ceiling prevents supraphysiological IGF-1
• Endogenous GH isoform profile: includes 20 kDa isoform

rhGH is more appropriate for GHD models; secretagogues are more appropriate for modeling physiological GH axis restoration in aging.

Compound 5: NAD+/NMN (Cellular Longevity)#

The NAD+ decline in aging#

NAD+ declines 30–50% in most tissues between young adulthood and old age. Consequences:

• Sirtuin activity falls → PGC-1α less activated → mitochondrial biogenesis slows
• SIRT3 less active → Complex I accumulates acetylation → ETC inefficiency → more ROS
• SIRT6 less active → less H3K56 deacetylation → less DNA DSB repair → genomic instability
• SIRT1 less active → NF-κB more active → inflammaging

NMN/NAD+ supplementation rationale#

NMN (SC in rodents) restores tissue NAD+ toward young-adult levels:

• Liver: highest response (30–60% increase)
• Muscle: 30–50% increase
• Brain: modest but real increase

Restored NAD+ → reactivated sirtuins → mitochondrial quality restoration, improved DNA repair, reduced inflammation.

Aging relevance: directly addresses the NAD+ deficit of aging. The Gomes 2013, Yoshino 2011, and Mills 2016 data demonstrate reversal of multiple aging parameters with NMN in aged mice.

Mechanism Map: Non-Overlapping Pathways#

No two compounds in this stack share a primary mechanism. This is the key criterion for a rational multi-compound protocol.

Full Anti-Aging Stack Protocol#

Rodent anti-aging protocol (aged rat model, 18–24 months)#

Staggering injections#

BPC-157 + TB-500 (morning) → Ipamorelin + CJC-1295 (onset of dark cycle + 8h) → NMN (either timing is fine)

Vehicle#

• BPC-157, TB-500, Ipamorelin, CJC-1295: reconstitute in bacteriostatic water
• NMN: dissolve in sterile saline or PBS

Endpoint Selection for Anti-Aging Research#

Considerations and Caveats#

Polypharmacy complexity#

Combining 5 compounds makes it difficult to attribute specific effects to specific compounds. For mechanistic studies, run single-compound and pairwise combination arms alongside the full stack.

Order effects#

Some compounds interact with the same downstream signaling nodes:

• BPC-157 promotes angiogenesis (FAK-paxillin → VEGF upregulation); Ipamorelin/CJC-1295 also promotes some VEGF via IGF-1. These may be additive but monitoring for unexpected interaction is prudent.
• NAD+/NMN → SIRT1 → PGC-1α (mitochondrial biogenesis); IGF-1 → mTOR can oppose some autophagy benefits of SIRT1 activation. This is a potential tension: IGF-1 activates mTOR (reduces autophagy); NAD+/SIRT1 activates autophagy. The net effect requires empirical measurement.

Species translation#

Rodent anti-aging research translates imperfectly to humans. Mice and rats have higher basal metabolic rates, different aging trajectories, and different NMN/NR pharmacokinetics. Human-translatable anti-aging research requires independent validation.

Key References#

1. López-Otín C, et al. (2023). "Hallmarks of aging: An expanding universe." Cell, 186(2):243–278.

2. Sikiric P, et al. (2018). "Brain-gut axis and pentadecapeptide BPC 157." Current Pharmaceutical Design, 24(18):1930–1945.

3. Goldstein AL, Hannappel E, Kleinman HK. (2005). "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues." Trends in Molecular Medicine, 11(9):421–429.

4. Raun K, et al. (1998). "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology, 139(5):552–561.

5. Mills KF, et al. (2016). "Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice." Cell Metabolism, 24(6):795–806.

Research Use Only: All compounds referenced are sold exclusively for in-vitro research and laboratory use. Not for human consumption. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · September 2026 · Category: Research Protocols & Science